Vertex Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. 

CEO
Reshma Kewalramani
CEOReshma Kewalramani
Employees
6,400
Employees6,400
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1989
Founded1989
Employees
6,400
Employees6,400

VRTX Key Statistics

Market cap
134.05B
Market cap134.05B
Price-Earnings ratio
31.77
Price-Earnings ratio31.77
Dividend yield
Dividend yield
Average volume
973.52K
Average volume973.52K
High today
High today
Low today
Low today
Open price
$528.29
Open price$528.29
Volume
0.00
Volume0.00
52 Week high
$560.25
52 Week high$560.25
52 Week low
$374.17
52 Week low$374.17

Stock Snapshot

The current Vertex Pharmaceuticals(VRTX) stock price is $527.00, with a market capitalization of 134.05B. The stock trades at a price-to-earnings (P/E) ratio of 31.77.

During the trading day, Vertex Pharmaceuticals(VRTX) stock saw an opening price of $528.29, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 973.52K.

The stock's 52-week range extends from a low of $374.17 to a high of $560.25.

The stock's 52-week range extends from a low of $374.17 to a high of $560.25.

VRTX News

Nasdaq 14h
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock

Key Points Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growt...

Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock
TipRanks 4d
Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts

Analysts are intrested in these 5 stocks: ( (ACRS) ), ( (EYPT) ), ( (VRTX) ), ( (GTLB) ) and ( (NB) ). Here is a breakdown of their recent ratings and the ratio...

Nasdaq 5d
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

Key Points Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded afte...

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?

Analyst ratings

76%

of 33 ratings
Buy
75.8%
Hold
18.2%
Sell
6.1%

People also own

Based on the portfolios of people who own VRTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.